Using these two established human in vitro BBB models, we investigated the effects of anti-HER2-targeted therapies for the treatment of advanced HER2-positive breast cancer to examine their influence on BBB integrity and possible consequences for cerebral metastases in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.